Investor Confidence

Prothena's financial strength also contributes to improving investor sentiment, with a $50 million milestone payment from Novo Nordisk and approximately $330 million in cash and cash equivalents as of the first quarter of 2026. Management believes this capital is sufficient to fund operations for at least the next year.